A pharma giant is moving past one patent cliff — but another is already looming
Source: CNBC Business
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
This is aggregated or syndicated coverage. Reporting and media belong to the original publisher.
Read the original source at CNBC Business